Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1567-1577

  Wong, John C T ^a   Hasan, Mohammad R ^a,b   Rahman, Mahbuba ^a,b   Yu, Angel C ^a,b   Chan, Simon K ^b   Schaeffer, David F ^a   Kennecke, Hagen F ^c   Lim, Howard J ^c   Owen, David ^a   Tai, Isabella T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

adenoma; cellular senescence; colorectal cancer; nucleophosmin 1; p53

Indexed keywords

MESSENGER RNA; NUCLEOPHOSMIN; PROTEIN P53; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL VIABILITY; CLINICAL FEATURE; COLON ADENOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; UPREGULATION;

ADENOMA; CELLULAR SENESCENCE; COLORECTAL CANCER; NUCLEOPHOSMIN 1; P53;

ADENOMA; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84880252470     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28180     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. Cancer J Clin 2012; 62: 10-29.
2. Sillars-Hardebol AH, Carvalho B, de Wit M, et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol 2010; 31: 89-96.
3. Chan SK, Griffith OL, Tai IT, et al. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008; 17: 543-52.
4. Wong JC, Chan SK, Schaeffer DF, et al. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer. Clin Cancer Res 2011; 17: 4167-76.
5. Lindstrom MS,. NPM1/B23: A multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int 2011; 2011: 195209.
6. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-66.
7. Marcucci G, Haferlach T, Dohner H,. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-86.
8. Skaar TC, Prasad SC, Sharareh S, et al. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol 1998; 67: 391-402.
9. Shields LB, Gercel-Taylor C, Yashar CM, et al. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig 1997; 4: 298-304.
10. Subong EN, Shue MJ, Epstein JI, et al. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999; 39: 298-304.
11. Pianta A, Puppin C, Franzoni A, et al. Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun 2010; 397: 499-504.
12. Kim CK, Nguyen TL, Lee SB, et al. Akt2 and nucleophosmin/B23 function as an oncogenic unit in human lung cancer cells. Exp Cell Res 2011; 317: 966-75.
13. Yun JP, Miao J, Chen GG, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 2007; 96: 477-84.
14. Tsui KH, Juang HH, Lee TH, et al. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin 2008; 29: 364-70.
15. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
16. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-22.
17. Niles RM, Wilhelm SA, Steele GD, Jr, et al. Isolation and characterization of an undifferentiated human colon carcinoma cell line (MIP-101). Cancer Investig 1987; 5: 545-52.
18. Chan JM, Ho SH, Tai IT,. Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53. Carcinogenesis 2010; 31: 812-19.
19. Hasan MR, Ho SH, Owen DA, et al. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. International journal of cancer. J Int Cancer 2011; 129: 2115-23.
20. Gary RK, Kindell SM,. Quantitative assay of senescence-associated beta-galactosidase activity in mammalian cell extracts. Anal Biochem 2005; 343: 329-34.
21. Tai IT, Dai M, Owen DA, et al. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Investig 2005; 115: 1492-502.
22. Taghizadeh F, Tang MJ, Tai IT,. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther 2007; 6: 309-17.
23. Wu MH, Chang JH, Yung BY,. Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 2002; 23: 93-100.
24. Colombo E, Bonetti P, Lazzerini Denchi E, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25: 8874-86.
25. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
26. Harper JW, Elledge SJ, Keyomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
27. Nozawa Y, Van Belzen N, Van der Made AC, et al. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996; 178: 48-52.
28. Sakai A, Otani M, Miyamoto A, et al. Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics 2012; 75: 806-18.
29. Jiang PS, Yung BY,. Down-regulation of nucleophosmin/B23 mRNA delays the entry of cells into mitosis. Biochem Biophys Res Commun 1999; 257: 865-70.
30. Collado M, Serrano M,. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-7.
31. Colombo E, Alcalay M, Pelicci PG,. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011; 30: 2595-609.
32. Kang JY, Kim JJ, Jang SY, et al. The p53-p21(Cip1/WAF1) pathway is necessary for cellular senescence induced by the inhibition of protein kinase CKII in human colon cancer cells. Mol Cells 2009; 28: 489-94.
33. Szebeni A, Hingorani K, Negi S, et al. Role of protein kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein b23. J Biol Chem 2003; 278: 9107-15.
34. Munstermann U, Fritz G, Seitz G, et al. Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J Biochem 1990; 189: 251-7.
35. Colombo E, Marine JC, Danovi D, et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-33.
36. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25: 1258-71.